{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:12:09Z","timestamp":1772831529086,"version":"3.50.1"},"reference-count":86,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2020,10,27]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Bortezomib is a reversible inhibitor of proteasome proteins in mammalian\ncells. Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal\nhomeostatic mechanism and thereby, causing cell death. Currently, Bortezomib is prescribed for patients\nwith multiple myeloma and mantle cell lymphoma.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This assessment highlights the overview of the recent patents of Bortezomib. This review\nincludes patents grouped in sections like product patents, process patent, composition related\npatents as well as the treatment methodology. The objective of this article is to facilitate researchers\nwith all existing patents at a single place.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Data were searched from various online databases. In which, paid databases include\nSciFinder\u00ae and Orbit\u00ae. Free databases include Patentscope\u00ae (WIPO), Worldwide Espacenet\u00ae (EPO),\nGoogle Patents and InPASS (Indian patent database).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Several new processes and composition related patents of Bortezomib have been recently\npatented as its orange-book listed patents are going to soon expire during July 2022. Further, due\nto the problem of oxidation during development and long-term storage of Bortezomib formulation,\na number of excipients are tried in these patents to stabilize the same. However, there is still a need\nfor further development of an improved formulation of Bortezomib with better characteristics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Extensive research has been carried out on various processes for preparing Bortezomib\nand the composition thereof. This type of dynamic research will clear the path for many\ngeneric players in the United States, which lead to the reduction of the price of the composition and\nthereby enhancing global health care at cheaper prices.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892815666200401113805","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T18:14:50Z","timestamp":1585764890000},"page":"113-131","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bortezomib \u2013 First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature"],"prefix":"10.2174","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-2618","authenticated-orcid":true,"given":"Pratik A.","family":"Vora","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Dharamsi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Brazier Y.","unstructured":"Brazier Y.;  What are the different types of tumor? (Access on: September 30, 2019).","journal-title":"What are the different types of tumor?"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"Moreau P.","year":"2012","unstructured":"Moreau P.; Richardson P.G.; Cavo M.; Orlowski R.Z.; San Miguel J.F.; Palumbo A.; Harousseau J.L.; Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012,120(5),947-959","journal-title":"Blood"},{"key":"ref=3","unstructured":"Velcade FDA Label, Available from:   (Access on: October 1, 2019)."},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1078-0432.CCR-19-1044","volume":"26","author":"Reid E.G.","year":"2020","unstructured":"Reid E.G.; Suazo A.; Lensing S.Y.; Dittmer D.P.; Ambinder R.F.; Maldarelli F.; Gorelick R.J.; Aboulafia D.; Mitsuyasu R.; Dickson M.A.; Wachsman W.; Pilot trial AMC-063: Safety and efficacy of bortezomib in AIDS-associated Kaposi sarcoma. Clin Cancer Res 2020,26(3),558-565","journal-title":"Clin Cancer Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/tmj.tmj_21_17","volume":"45","author":"Bassiony E.","year":"2017","unstructured":"Bassiony E.; Barakat A.; Ghannam A.; Abozena E.; Bortezomib in multiple myeloma: Treatment response and survival outcome. Tanta Med J 2017,45(3),129-134","journal-title":"Tanta Med J"},{"key":"ref=6","unstructured":"Orange Book Database(Accessed on: October 2, 2019)."},{"key":"ref=7","author":"Adams J","year":"1996","unstructured":"Adams J; Ma Y-T; Stein R; Baevsky M; Grenier L; Plamondon L; Boronic ester and acid compounds, synthesis and uses. WO9613266, 1996","journal-title":"WO9613266,"},{"key":"ref=8","author":"Pickersgill IF","year":"2005","unstructured":"Pickersgill IF; Bishop J; Koellner C; Synthesis of peptidyl boronic acids and esters. WO2005097809, 2005","journal-title":"WO2005097809,"},{"key":"ref=9","author":"Palle RV","year":"2009","unstructured":"Palle RV; Kadaboina R; Murki V; Preparation of bortezomib in crystalline form. WO2009036281, 2009","journal-title":"WO2009036281,"},{"key":"ref=10","author":"Zhao J","year":"2013","unstructured":"Zhao J; Du Y; Zhao Y; Cai K; Wu C; Yang J; Manufacture method of high optical purity bortezomib and its intermediate. CN103304629, 2013","journal-title":"CN103304629,"},{"key":"ref=11","author":"Rao DR","year":"2014","unstructured":"Rao DR; Kankan RN; Pathi SL; Puppala R; Lawrence Louis  Process for preparing of bortezamib. WO2014041324, 2014","journal-title":"WO2014041324,"},{"key":"ref=12","author":"Dhar DS","year":"2015","unstructured":"Dhar DS; Kamlesh SK; Dnyaneshwar NS; An improved process for preparation of bortezomib. IN972\/MUM\/2013 2015","journal-title":"IN972\/MUM\/2013"},{"key":"ref=13","author":"Zhao X","year":"2013","unstructured":"Zhao X; Li X; Zhao Y; Synthesis method of high-purity bortezomib and its intermediates. CN103012551, 2013","journal-title":"CN103012551,"},{"key":"ref=14","author":"Zou Y","year":"2019","unstructured":"Zou Y; Huang Q; Jiang X; Tang Y; Zou C; Yuan Q; Impurity of bortezomib and preparation method thereof. CN109134601, 2019","journal-title":"CN109134601,"},{"key":"ref=15","author":"Ravi JRR","year":"2008","unstructured":"Ravi JRR; Pulla Reddy M; Adibatla Kali Satya BR; Benkaiah Chowdary N; Polymorphic forms of bortezomib and process for their preparation. WO2008075376, 2008","journal-title":"WO2008075376,"},{"key":"ref=16","author":"Reddy BP","year":"2011","unstructured":"Reddy BP; Reddy KR; Reddy DM; Reddy RR; Ramachandra P; Krishna BV; Polymorphs of bortezomib. WO2011099018, 2011","journal-title":"WO2011099018,"},{"key":"ref=17","author":"Jamjanam SR","year":"2012","unstructured":"Jamjanam SR; Moturu VRM; Dammalapati VLNR; Gorantla SR; Preparation of a novel crystalline form of bortezomib and pharmaceutical composition thereof. WO2012131707, 2012","journal-title":"WO2012131707,"},{"key":"ref=18","author":"Xie T","year":"2015","unstructured":"Xie T; Xu Z; Zhou H; Chen F; One kind of bortezomib crystal form, and its preparation method, pharmaceutical compositions and application in antitumor drugs. CN104693271, 2015","journal-title":"CN104693271,"},{"key":"ref=19","author":"Son HJ","year":"2015","unstructured":"Son HJ; Park YK; Kim Y-M; Hwang J-M; Kim JH; Novel crystalline form of bortezomib and preparation method thereof. WO2015122702, 2015","journal-title":"WO2015122702,"},{"key":"ref=20","author":"Ding J","year":"2015","unstructured":"Ding J; Xu W; Zhuang X; Chen X; Dextran-bortezomib conjugate medicine and its preparation method. CN104958768, 2015","journal-title":"CN104958768,"},{"key":"ref=21","author":"Shrawat VK","year":"2014","unstructured":"Shrawat VK; A process for the preparation of crystalline bortezomib. WO201407613, 2014","journal-title":"WO201407613,"},{"key":"ref=22","author":"Ravi JRR","year":"2014","unstructured":"Ravi JRR; Kondaveeti S; Adibhatla KSBR; Muddasani PR; Nannapaneni VC; Stable and pure polymorphic form of bortezomib. WO2014097306, 2014","journal-title":"WO2014097306,"},{"key":"ref=23","author":"Shivakumar P","year":"2014","unstructured":"Shivakumar P; Ramakrishnaiah S; Alampalli B; Chaturvedi A.; Bortezomib injection formulations. WO2014102755, 2014","journal-title":"WO2014102755,"},{"key":"ref=24","author":"Joo SH","year":"2016","unstructured":"Joo SH; Stable crystalline form bortezomib. KR101741403, 2016","journal-title":"KR101741403,"},{"key":"ref=25","author":"Furuya T","year":"2019","unstructured":"Furuya T; Abe M; Manufacturing method for bortezomib crystals. WO2019151133, 2019","journal-title":"WO2019151133,"},{"key":"ref=26","author":"Farag SS","year":"2010","unstructured":"Farag SS; Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma. WO2010056733, 2010","journal-title":"WO2010056733,"},{"key":"ref=27","author":"Shaughnessy JD","year":"2010","unstructured":"Shaughnessy JD; Barlogie B; Qu P; Uses of bortezomib in predicting survival in multiple myeloma patients. WO2010078531, 2010","journal-title":"WO2010078531,"},{"key":"ref=28","author":"Liu X","year":"2016","unstructured":"Liu X; Li X; Qin Q; Gao C; Yu X.; Pharmaceutical use of a dicycloplatin (DCP) for the prophylaxis or treatment of proliferative diseases. WO2016172393, 2016","journal-title":"WO2016172393,"},{"key":"ref=29","author":"Won PJ","year":"2017","unstructured":"Won PJ; Park WJ; Composition for relief and treatment of liver injury comprising bortezomib as a active ingredient. KR101695237, 2017","journal-title":"KR101695237,"},{"key":"ref=30","author":"Kim NS","year":"2016","unstructured":"Kim NS; Park J-S; Yi J-M; Composition, containing Lithospermum erythrorhizon extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy. WO2016182139, 2016","journal-title":"WO2016182139,"},{"key":"ref=31","author":"Chen T","year":"2019","unstructured":"Chen T; Shachar Y; Intratumoral delivery of bortezomib into brain tumor by pump implanted in brain. WO2019148181, 2019","journal-title":"WO2019148181,"},{"key":"ref=32","author":"Xie H","year":"2019","unstructured":"Xie H; Cakana A.; Methods of treating multiple myeloma. US20190298827, 2019","journal-title":"US20190298827,"},{"key":"ref=33","author":"Gupta S.","year":"2002","unstructured":"Gupta S.; Lyophilized formulation of sugar-containing boronic acid compounds. WO2002059130, 2002","journal-title":"WO2002059130,"},{"key":"ref=34","author":"Plamondon L","year":"2002","unstructured":"Plamondon L; Grenier L; Adams J; Gupta SL; Lyophilized formulation of boronic acid compounds. WO2002059131, 2002","journal-title":"WO2002059131,"},{"key":"ref=35","author":"Zalipsky S","year":"2006","unstructured":"Zalipsky S; Martin F; Liposomal formulation of bortezomib (PS-341). WO2006052733, 2006","journal-title":"WO2006052733,"},{"key":"ref=36","author":"Sun L","year":"2008","unstructured":"Sun L; Sun Z; Zhang W; Antitumor sustained-release injection containing taxol and bortezomib. CN101301472, 2008","journal-title":"CN101301472,"},{"key":"ref=37","author":"Hou H","year":"2009","unstructured":"Hou H; Sun Q; Sun Z; Bortezomib and alkylating agent composite sustained-release injection with drug delivery delayed greatly and preparation method thereof. CN101336926, 2009","journal-title":"CN101336926,"},{"key":"ref=38","author":"Mao H","year":"2009","unstructured":"Mao H; Wang M; Chen Y; Antitumor sustained-release injection containing bortezomib and topoisomerase inhibitors. CN101336893, 2009","journal-title":"CN101336893,"},{"key":"ref=39","author":"Soppimath K","year":"2011","unstructured":"Soppimath K; Pejaver S; Patel KR; Stable bortezomib formulations. WO2011116286, 2011","journal-title":"WO2011116286,"},{"key":"ref=40","author":"Usayapant A","year":"2012","unstructured":"Usayapant A; Bowman D; Bortezomib formulations stabilized with boric. WO2012047845, 2012","journal-title":"WO2012047845,"},{"key":"ref=41","author":"Xia F.","year":"2013","unstructured":"Xia F.; Pharmaceutical composition containing bortezomib for treating T cell lymphoma. CN103191405, 2013","journal-title":"CN103191405,"},{"key":"ref=42","author":"Zhao J","year":"2013","unstructured":"Zhao J; Cai J; Zong Z; Ji T; Jia Y; Bortezomib lyophilized composition and preparation method thereof. CN103446068, 2013","journal-title":"CN103446068,"},{"key":"ref=43","author":"Yeon WK","year":"2014","unstructured":"Yeon WK; Wook KD; Pyo HE; Oral pharmaceutical composition comprising bortezomib. KR20140057048, 2014","journal-title":"KR20140057048,"},{"key":"ref=44","author":"Puppala R","year":"2014","unstructured":"Puppala R; Pathi SL; Rao DR; Kankan RN; Process for the preparation of bortezomib mannitol ester substantially free of the degradation impurity. WO2014170628, 2014","journal-title":"WO2014170628,"},{"key":"ref=45","author":"Zhong Z","year":"2013","unstructured":"Zhong Z; Chen Y; Wang X; Ma Y; Bortezomib medicinal composition and preparation method thereof. CN103212055, 2013","journal-title":"CN103212055,"},{"key":"ref=46","author":"Chen Q","year":"2013","unstructured":"Chen Q; Zong Z; Jia Y; Bortezomib lyophilized composition and its preparation method. CN103070835, 2013","journal-title":"CN103070835,"},{"key":"ref=47","author":"Zaludek B.","year":"2015","unstructured":"Zaludek B.; Pharmaceutical compositions comprising bortezomib. WO2015025000, 2015","journal-title":"WO2015025000,"},{"key":"ref=48","author":"Yuan S","year":"2014","unstructured":"Yuan S; Yang X; Wang L; Method for preparing bortezomib powder for injection. CN103505424, 2014","journal-title":"CN103505424,"},{"key":"ref=49","author":"Shivakumar P","year":"2016","unstructured":"Shivakumar P; Ramakrishnaiah S; Alampalli B; Chaturvedi AK; Bortezomib formulations. WO2016059515, 2016","journal-title":"WO2016059515,"},{"key":"ref=50","author":"Yao Z","year":"2015","unstructured":"Yao Z; Luo Y; Yan F; Zhang H; Che B; Pharmaceutical composition containing bortezomib and preparation method thereof. CN105056205, 2015","journal-title":"CN105056205,"},{"key":"ref=51","author":"Shaik RA","year":"2016","unstructured":"Shaik RA; Chaurasiya A; Saha A; Patel BV; Bhagwatwar H; Pillai SA; Stable liquid ready-to-use injectable formulation of bortezomib. WO2016001905, 2016","journal-title":"WO2016001905,"},{"key":"ref=52","author":"Pasqua L","year":"2016","unstructured":"Pasqua L; Leggio A; Liguori A; Morelli C; Ando S.; Bortezomib-based delivery system. WO2016174693, 2016","journal-title":"WO2016174693,"},{"key":"ref=53","author":"Chen Z","year":"2016","unstructured":"Chen Z; Zheng Q; Wang S; Zhao X; Bortezomib injection agent and preparation method thereof. CN105496960, 2016","journal-title":"CN105496960,"},{"key":"ref=54","author":"Shivakumar P","year":"2016","unstructured":"Shivakumar P; Dasari N; Kulkarni R; Chaturvedi AK; Bortezomib pharmaceutical formulations comprising orthophosphoric acid for treating cancer. WO2016059515, 2016","journal-title":"WO2016059515,"},{"key":"ref=55","author":"Mudri D","year":"2016","unstructured":"Mudri D; Vince N; Malic acid esters of bortezomib. EP3031811, 2016","journal-title":"EP3031811,"},{"key":"ref=56","author":"Gondaliya DP","year":"2016","unstructured":"Gondaliya DP; Gurjar MK; Mehta SS; Patel HP; Patel HI; Patel NM; Pharmaceutical composition of bortezomib. WO2016110870, 2016","journal-title":"WO2016110870,"},{"key":"ref=57","author":"Sun J","year":"2014","unstructured":"Sun J; Wang Y; Wu Z; Bortezomib sustained-release preparation and its preparation method. CN103656668, 2014","journal-title":"CN103656668,"},{"key":"ref=58","author":"Jae PW","year":"2016","unstructured":"Jae PW; Won PJ; Composition for preventing or treating obesity or non-alcoholic fatty liver, containing bortezomib. KR20160117839 2016","journal-title":"KR20160117839"},{"key":"ref=59","author":"Chandrashekhar K","year":"2016","unstructured":"Chandrashekhar K; Nagaraju B; Stable liquid pharmaceutical compositions of bortezomib. WO2016166653, 2016","journal-title":"WO2016166653,"},{"key":"ref=60","author":"Zhang G","year":"2015","unstructured":"Zhang G; Zhao Z; Cheng Z.; A kind of bortezomib lyophilized powder injection and the production method thereof. CN104546744, 2015","journal-title":"CN104546744,"},{"key":"ref=61","author":"Yuan H","year":"2016","unstructured":"Yuan H; Wang Y; Dong L; Sun Y; Sun C; Lyophilized preparation of bortezomib and preparation method thereof. CN106176637, 2016","journal-title":"CN106176637,"},{"key":"ref=62","author":"Sun Y","year":"2017","unstructured":"Sun Y; Wang Y; Dong L; Huang Y; Yuan H; Bortezomib freeze-dried powder injection and its making process. CN106309385, 2017","journal-title":"CN106309385,"},{"key":"ref=63","author":"Schridde E.","year":"2017","unstructured":"Schridde E.; Ready-to-use bortezomib solution. WO2017013208, 2017","journal-title":"WO2017013208,"},{"key":"ref=64","author":"Kanteepan P","year":"2017","unstructured":"Kanteepan P; Vekariya SL; Mandal JK; Mehta SP; Composition comprising bortezomib. US10314880, 2017","journal-title":"US10314880,"},{"key":"ref=65","author":"Katori K","year":"2017","unstructured":"Katori K; Kinoshita M; Isane M; Inoue H; Freeze-dried compositions containing bortezomib and tartaric acid prepared for reconstitution of pH-controlled pharmaceutical infection solution. JP2017057202, 2017","journal-title":"JP2017057202,"},{"key":"ref=66","author":"Ebetino F","year":"2017","unstructured":"Ebetino F; Boeckman R; Xing L; Xiao L; Boyce B; Bortezomib conjugates and methods using same. WO2017079262, 2017","journal-title":"WO2017079262,"},{"key":"ref=67","author":"Lu W","year":"2017","unstructured":"Lu W; Wang X; Xie C; Wei G; Hu X; Bortezomib water-soluble medicinal composition and preparation method and application method thereof to antitumor agents. CN107224569, 2017","journal-title":"CN107224569,"},{"key":"ref=68","author":"Liu C","year":"2013","unstructured":"Liu C; Zhuang H; Wang Y; Bortezomib pharmaceutical composition for injection. CN103142509, 2013","journal-title":"CN103142509,"},{"key":"ref=69","author":"Aydinlar T.","year":"2018","unstructured":"Aydinlar T.; Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex for use in treatment of cancers such as multiple myeloma and mantle cell lymphoma. WO2018038687, 2018","journal-title":"WO2018038687,"},{"key":"ref=70","author":"Lee JH","year":"2018","unstructured":"Lee JH; Cho TK; Ryu CY; Cho YD; Stable preparation containing bortezomib and preparation method therefor. WO2018164513, 2018","journal-title":"WO2018164513,"},{"key":"ref=71","author":"Kharbanda S","year":"2018","unstructured":"Kharbanda S; Shukla V; Kufe D; Singh H; Polymeric nanoparticles and antitumor uses thereof. WO2018085407, 2018","journal-title":"WO2018085407,"},{"key":"ref=72","author":"Gan Y","year":"2018","unstructured":"Gan Y; Zhu Q; Zhu C; Ji L; Jin Y; Guo S; Bortezomib pharmaceutical composition and applications thereof. WO2018108164, 2018","journal-title":"WO2018108164,"},{"key":"ref=73","author":"Zhao Z","year":"2015","unstructured":"Zhao Z; Hao G; Shao J; Fan F; Wu S; Bortezomib freeze-dried powder injection and preparation method thereof. CN104414982, 2015","journal-title":"CN104414982,"},{"key":"ref=74","author":"Nazarenko AB","year":"2018","unstructured":"Nazarenko AB; Kinasov DG; Ladygin VV; Kornev KO; Zakoryukin NV; Bortezomib lyophilizate production method and a bortezomib-containing pharmaceutical composition in the form of stable lyophilizated product produced by said method. RU2659160, 2018","journal-title":"RU2659160,"},{"key":"ref=75","author":"Yoshioka Y","year":"2018","unstructured":"Yoshioka Y; Fujiki D; Bortezomib liquid preparation comprising propylene glycol and ascorbic acid compound. JP2018168088, 2018","journal-title":"JP2018168088,"},{"key":"ref=76","author":"Hidaka A","year":"2018","unstructured":"Hidaka A; Motoyama J; Preparation of pharmaceutical composition containing bortezomib. JP2018177649A, 2018","journal-title":"JP2018177649A,"},{"key":"ref=77","author":"Hou L.","year":"2018","unstructured":"Hou L.; Bortezomib phosphatide complex and preparation method and application thereof. CN109045272, 2018","journal-title":"CN109045272,"},{"key":"ref=78","author":"Sun C","year":"2017","unstructured":"Sun C; Wang X; Yuan H; Sun Y; Meng W; Bortezomib pharmaceutical composition and preparation method thereof. CN106265536, 2017","journal-title":"CN106265536,"},{"key":"ref=79","author":"Li N","year":"2019","unstructured":"Li N; Wang J; Li F; Bortezomib lyophilized powder for injection and its preparation method. CN109364030, 2019","journal-title":"CN109364030,"},{"key":"ref=80","author":"Kwang KK","year":"2019","unstructured":"Kwang KK; Eun KY; Composition for preventing, improving or treating atopic skin diseases containing proteasome inhibitor as active ingredient. KR101953671, 2019","journal-title":"KR101953671,"},{"key":"ref=81","author":"Li N","year":"2019","unstructured":"Li N; Gui J; Shi X; Freeze-drying process of bortezomib freeze-dried powder for injection. CN109453125, 2019","journal-title":"CN109453125,"},{"key":"ref=82","author":"Jae PW","year":"2019","unstructured":"Jae PW; Keun PI; Composition comprising bortezomib or its pharmaceutically acceptable salt as active ingredient for inhibiting multidrug resistance. KR20190027148, 2019","journal-title":"KR20190027148,"},{"key":"ref=83","author":"Kharbanda S","year":"2019","unstructured":"Kharbanda S; Singh H; Polymeric nanoparticles comprising bortezomib. WO2019104001, 2019","journal-title":"WO2019104001,"},{"key":"ref=84","author":"Hattori H.","year":"2019","unstructured":"Hattori H.; Lyophilized pharmaceutical composition comprising bortezomib. JP2019085338, 2019","journal-title":"JP2019085338,"},{"key":"ref=85","author":"Serda RE","year":"2019","unstructured":"Serda RE; Noureddine A; A high capacity platform for immunogenic cancer cell death using siliceous nanoparticles comprising TLR ligand or other immunostimulant. WO2019173391, 2019","journal-title":"WO2019173391,"},{"key":"ref=86","author":"Mandal JK","year":"2019","unstructured":"Mandal JK; Mehta SP; Composition comprising bortezomib. US20190290718, 2019","journal-title":"US20190290718,"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180632","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180632\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T14:16:58Z","timestamp":1616077018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180632\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892815666200401113805","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}